Predictors of mortality after acute hip fracture
To identify determinants of mortality after hip fracture, we performed a multicenter, retrospective study of 390 Medicare beneficiaries. Independent predictors of 30-day mortality included a history of congestive heart failure (odds ratio [OR] 32; 95% confidence interval [CI] 5, 192), angina (OR 26; 95% CI 4, 184), or chronic pulmonary disease (OR 11; 95% CI 2, 62). Postoperative use of aspirin was- associated with a reduced risk of mortality (OR 0.24; 95% CI 0.08, 0.70). Cardiovascular events were the presumed cause of 63% of in-hospital deaths. Aspirin may have significant potential to reduce mortality in this population and deserves further study.
Key wordship fracture mortality outcome aspirin
Unable to display preview. Download preview PDF.
- 2.Koval KJ, Zuckerman JD. Functional recovery after fracture of the hip. J Bone Joint Surg. 1994;76-A:751–8.Google Scholar
- 5.Kenzora JE, McCarthy RE, Lowell JD, Sledge C. Hip fracture mortality: relation to age, treatment, preoperative illness, time of surgery, and complications. Clin Orthop Rel Res. 1984;186:45–56.Google Scholar
- 7.Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopedic, and urologic survey. N Engl J Med. 1988;318:1162–73.PubMedCrossRefGoogle Scholar
- 8.Claget GP, Anderson FA, Heit J, Levine MN, Wheeler HB. Prevention of venous thromboembolism. Chest. 1995;108:312S-34S.Google Scholar
- 13.Willard JE, Lange RA, Hillis LD. The use of aspirin in ischemic heart disease. N Engl J Med. 1993;327:175–81.Google Scholar
- 15.Anonymous. Aspirin for prevention of myocardial infarction. Medical Lett. 1995;37:14–6.Google Scholar
- 16.Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81–106.Google Scholar
- 18.MacMahon S, Rodgers A, Collins R, Farrell B. Antiplatelet therapy to prevent thrombosis after hip fracture: rationale for a randomised trial. J Bone Joint Surg Br. 1994;76-B:521–4.Google Scholar
- 19.Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ. 1994;308:235–46.Google Scholar